MeasurementsAge, sex, vital signs and medical history of all patients included in the study were recorded in a digital form.
Outcome measuresOur primary aim in this study is to determine the relationship between SI and 30-day mortality. Our secondary aim is to determine the relationship between mortality and the data (SI, SpO2 and chronic diseases) that can be obtained in ED triage in COVID −19 patients.
Statistical analysisIBM SPSS Statistics 25 (Chicago, IL) software was used for statistical analysis. CHAID analysis was used in Decision Tree methods. p < 0.01 was considered statistically significant. Within the scope of the research, the data obtained in the triage and the literature were taken into consideration while determining the variables related to the regression model
Objective:
This study compared the prognostic performances of the Brescia-COVID Respiratory Severity Scale (BCRSS) and the Quick COVID-19 Severity Index (qCSI) scores in hospitalized patients diagnosed with COVID-19.
Methods:
The data of all adult patients (over 18 years of age) who were admitted into a state hospital with confirmed COVID-19 between May 1, 2020 and October 31, 2020 were retrospectively examined. The area under the receiver operating characteristic (ROC) curve, known as the area under the curve (AUC), was used to assess the BCRSS prediction rule and the qCSI score to assess the discriminatory power in predicting in-hospital mortality and intensive care unit (ICU) admission.
Results:
There were 341 patients included in this study. The mean age of the patients was 58.2 ± 17.2, of which 165 were men and 176 were women, and 61.3% of patients had at least one comorbidity. The most common comorbidity was hypertension. The predictive power scores of BCRSS and qCSI were found as very good in terms of in-hospital mortality (AUC 0.804 and 0.847, respectively) and likewise in terms of ICU admission (AUC 0.842 and 0.851, respectively).
Conclusion:
Both BCRSS and qCSI scoring systems were found to be successful in predicting in-hospital mortality and ICU admission in our patient population.
The existence of a new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first reported in China and later spread throughout the world straining the health systems of many countries. 1 The viral pneumonia associated with SARS-CoV-2 has been officially named Coronavirus disease 2019 (COVID-19). 2 During the pandemic period, difficulties were experienced in the provision of health services because of excessive patient admissions in hospitals and emergency departments (EDs).In the first reports, it was stated that ~25% of patients required an intensive care unit (ICU). 3 Mortality in hospitalised COVID-19
Objective:
Healthcare workers (HCWs), are often seen as the most reliable source of vaccine-related information for their patients; nevertheless, various studies show that HCWs experience vaccine hesitation. In this study, the aim was to determine the reasons for vaccine hesitation among HCWs working in a large public hospital and its affiliated units in Istanbul.
Method:
A descriptive method for collecting qualitative data was designed for this study. The data of the HCWs was analyzed in line with the vaccine hesitancy factors put forward by the WHO.
Results:
The most important vaccine hesitancy theme that emerged was the fear and lack of confidence in the vaccines, which was expressed at a higher rate than any other theme in all HCWs. The most cited reason for fear/lack of confidence in the vaccine was the fear of its side effects. It was observed that the HCWs who reported hesitation about vaccination due to pregnancy and breastfeeding consisted of women. The second most common theme for vaccine hesitation was reported as an inconvenience in accessing the vaccines. Although HCWs have priority, they stated that their reason for vaccine hesitancy was due to heavy personal or workloads. The final theme was about complacency, or thinking they do not need the vaccine.
Conclusion:
Vaccine hesitation is a challenge that can be overcome with detailed monitoring and policy making. Although the vaccine seems to be more significant, we do not want to see vaccine hesitancy grow more than the vaccine itself.
In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in Wuhan, China, and it spread rapidly all over the world. 1 The World Health Organization (WHO) gave the name coronavirus disease-19 to the resultant disease and declared it to be an epidemic. 2 The first polymerase chain reaction (PCR)-positive COVID-19 case in Turkey was detected on March 11, 2020. 3 In some studies in the literature, it was reported that 14% of COVID-19 patients developed severe pneumonia, one in 20 patients had an intensive care unit (ICU) requirement and approximately 66% of critically ill patients died. [4][5][6] High mortality rates among critically ill patients and rapidly spreading disease raise concerns about ICU requirements, which may place pressure on healthcare system resources. 7 In order to make optimal treatment decisions, prognostic predictors of mortality among COVID-19 patients need to be identified in order to help assess the severity of the condition.Compared with the normal range, lower white blood cell (WBC) and lymphocyte counts but higher neutrophil counts have been found in COVID-19 patients. 8,9 In some recent studies, it has been reported that the neutrophil-to-lymphocyte ratio (NLR) is an independent prognostic factor for predicting outcomes of critical illness and in-hospital mortality among COVID-19 patients. 10,11
OBJECTIVEOur aim in this study was to determine the relationship between the prognosis and the NLR among COVID-19 patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.